TRADE NEWS: Agilent Technologies Introduces HaloPlex Next-Generation Sequencing Panels Targeting Cancer and Inherited Diseases for Research

Catalog and Custom Panels Enable Rapid, Targeted Genomics Analysis

TRADE NEWS: Agilent Technologies Introduces HaloPlex Next-Generation Sequencing Panels Targeting Cancer and Inherited Diseases for Research

<0> Agilent Technologies Inc.Susan Berg, +1 408-553-7093 </0>

Agilent Technologies Inc. (NYSE: A) today introduced a new series of targeting specific disease states. Two catalog products, the HaloPlex Cancer Research Panel and the HaloPlex Cardiomyopathy Research Panel, plus five predesigned research panels for arrhythmia, ICCG genomic regions, X chromosome, Noonan syndrome, and connective tissue disorders are now available. Used in combination with Agilent’s , the new panels enable laboratories to perform integrated data analysis, mapping and reporting with greater confidence, speed and flexibility.

“With the adoption of desktop sequencing, clinical research laboratories are increasingly interested in panels with predesigned content for routine analysis,” said Dr. Berivan Baskin, FACMG, FCCMG, clinical molecular geneticist at Uppsala University Hospital, who worked with Agilent to develop the panels. “These new HaloPlex panels, combined with Agilent’s analysis software, provide comprehensive content with high levels of sensitivity and specificity.”

“Clinical research laboratories commonly lack the time and resources necessary to individually define disease-related genes and incorporate them into their own custom sequencing panels,” said Jacob Thaysen, vice president and general manager of Agilent’s Genomics Solutions Division. “So we have been working closely with industry experts to develop these targeted disease panels to help these laboratories dramatically improve their workflows and research outcomes.”

HaloPlex target-enrichment solutions combine the speed and specificity of polymerase chain reaction-based systems with the scalability and capture-size flexibility of solution-based hybridization formats, eliminating the need for library preparation. This streamlined sequence-selective solution for next-generation sequencing helps to remove bottlenecks associated with targeted resequencing and eliminates the need for expensive, dedicated instrumentation or laborious protocols.

software programs are an integral part of Agilent’s complete solutions for next-generation sequencing target enrichment. SureDesign increases flexibility by allowing HaloPlex panel users to develop custom panels and incorporate additional predesigned genes/regions of interest to suit their laboratory’s individual needs. SureCall significantly reduces the data analysis hurdles faced by researchers, enabling simple and intuitive variant calling.

Agilent Technologies Inc. is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target-enrichment systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex and its same-day sample-to-sequencer workflow is well suited for next-gen desktop sequencers, whereas SureSelect’s ability to accurately capture whole exomes and whole methylomes in a single reaction pairs well with high-throughput next-gen sequencing systems. These are just two products arising from Agilent’s expertise in synthesizing custom complex mixtures of long oligonucleotides gained in microarray manufacturing. Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive product line for oligonucleotide flourescent in situ hybridization. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanlyzer to measure sample quality, a target-enrichment tool to speed next-gen sequencing, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at .

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at .

Suggested Articles

An assessment looking at 12 health systems that allow patients to download their health records to their smartphones via APIs finds modest uptake.

The National Institutes of Health-led All of Us precision medicine health research database project has enrolled 230,000 participants.

Hospitals must pursue a deliberate strategy for managing their public image—and a powerful tool for doing so is inpatient clinical data registries.